Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease

Open access

Abstract

To elucidate the relationship between cerebrospinal fluid (CSF) total‐tau (T‐tau) and phosphorylated tau (P‐tau) with the tau PET ligand 18 F‐AV‐1451 in Alzheimer's disease (AD), we examined 30 cognitively healthy elderly (15 with preclinical AD), 14 prodromal AD, and 39 AD dementia patients. CSF T‐tau and P‐tau were highly correlated ( R = 0.92, P < 0.001), but they were only moderately associated with retention of 18 F‐AV‐1451, and mainly in demented AD patients. 18 F‐AV‐1451, but not CSF T‐tau or P‐tau, was strongly associated with atrophy and cognitive impairment. CSF tau was increased in preclinical AD, despite normal 18 F‐AV‐1451 retention. However, not all dementia AD patients exhibited increased CSF tau, even though 18 F‐AV‐1451 retention was always increased at this disease stage. We conclude that CSF T‐tau and P‐tau mainly behave as biomarkers of “disease state”, since they appear to be increased in many cases of AD at all disease stages, already before the emergence of tau aggregates. In contrast, 18 F‐AV‐1451 is a biomarker of “disease stage”, since it is increased in clinical stages of the disease, and is associated with brain atrophy and cognitive decline.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201707809

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure EV1 Correlations between CSF T‐tau and P‐tau CSF P‐tau and T‐tau in different diagnostic groups, with slopes from linear regression models adjusted for age and sex.
Figure EV1 Correlations between CSF T‐tau and P‐tau CSF P‐tau and T‐tau in different diagnostic groups, with slopes from linear regression models adjusted for age and sex.CC BY · PubMed Central
Figure 1 Correlations between regional 18F‐AV‐1451 and CSF tau biomarkers A–LObserved data and correlations for CSF T‐tau by regional 18F‐AV‐1451, and for CSF P‐tau by regional 18F‐AV‐1451. The y‐axes show 18F‐AV‐1451 data in the a priori defined tau stage I–II, III, IV, V and VI regions, and in the merged tau stage I–V region. Each symbol represents one person. The fitted lines are from linear regression models adjusted for the interaction between the CSF biomarker and diagnosis, and age, sex and time between lumbar puncture and PET scan. P‐values from these models are shown, extracted for each diagnostic group (CN, controls; Pro AD, prodromal AD; AD dem, AD dementia). Corresponding β‐coefficients are presented in Table EV1.
Figure 1 Correlations between regional 18F‐AV‐1451 and CSF tau biomarkers A–LObserved data and correlations for CSF T‐tau by regional 18F‐AV‐1451, and for CSF P‐tau by regional 18F‐AV‐1451. The y‐axes show 18F‐AV‐1451 data in the a priori defined tau stage I–II, III, IV, V and VI regions, and in the merged tau stage I–V region. Each symbol represents one person. The fitted lines are from linear regression models adjusted for the interaction between the CSF biomarker and diagnosis, and age, sex and time between lumbar puncture and PET scan. P‐values from these models are shown, extracted for each diagnostic group (CN, controls; Pro AD, prodromal AD; AD dem, AD dementia). Corresponding β‐coefficients are presented in Table EV1.CC BY · PubMed Central
Figure 2 Voxel‐wise associations of 18F‐AV‐1451 and CSF tau biomarkers A–DAssociations of CSF T‐tau (A) and P‐tau (C) on 18F‐AV‐1451 uptake, adjusted for age, sex, diagnosis and time between lumbar puncture and PET scan. Associations of CSF T‐tau (B) and P‐tau (D) on 18F‐AV‐1451 uptake when also adjusting for atrophy (using cortical thickness in the “AD‐cortex” region). All results are shown at a statistical significance threshold of P < 0.001 (uncorrected).
Figure 2 Voxel‐wise associations of 18F‐AV‐1451 and CSF tau biomarkers A–DAssociations of CSF T‐tau (A) and P‐tau (C) on 18F‐AV‐1451 uptake, adjusted for age, sex, diagnosis and time between lumbar puncture and PET scan. Associations of CSF T‐tau (B) and P‐tau (D) on 18F‐AV‐1451 uptake when also adjusting for atrophy (using cortical thickness in the “AD‐cortex” region). All results are shown at a statistical significance threshold of P < 0.001 (uncorrected).CC BY · PubMed Central
Figure 3 Associations between tau biomarkers and neurodegeneration AVoxel‐wise association between GM intensity and 18F‐AV‐1451 uptake in the tau stage I–V composite region, adjusted for age, sex and diagnosis. The model yielded suprathreshold clusters in the posterior lateral temporal lobes, lateral parietal and occipital cortex, as well as the precuneus at a statistical threshold of P < 0.001 (uncorrected).B, CVoxel‐wise association between GM intensity and CSF T‐tau or P‐tau, adjusted for age, sex and diagnosis. The model with T‐tau as the independent variable produced small, scattered significant clusters in the precuneus, the middle cingulate gyrus, parietal and left temporal cortex. The model with P‐tau produced a similar pattern, except for the association in precuneus.
Figure 3 Associations between tau biomarkers and neurodegeneration AVoxel‐wise association between GM intensity and 18F‐AV‐1451 uptake in the tau stage I–V composite region, adjusted for age, sex and diagnosis. The model yielded suprathreshold clusters in the posterior lateral temporal lobes, lateral parietal and occipital cortex, as well as the precuneus at a statistical threshold of P < 0.001 (uncorrected).B, CVoxel‐wise association between GM intensity and CSF T‐tau or P‐tau, adjusted for age, sex and diagnosis. The model with T‐tau as the independent variable produced small, scattered significant clusters in the precuneus, the middle cingulate gyrus, parietal and left temporal cortex. The model with P‐tau produced a similar pattern, except for the association in precuneus.CC BY · PubMed Central
Figure EV2 Associations between atrophy and CSF and PET tau, adjusted for the other tau modality A, BVBM analyses for 18F‐AV‐1451 when adjusted for CSF T‐tau or P‐tau.C, DVBM analyses for CSF T‐tau and P‐tau when adjusted for 18F‐AV‐1451.
Figure EV2 Associations between atrophy and CSF and PET tau, adjusted for the other tau modality A, BVBM analyses for 18F‐AV‐1451 when adjusted for CSF T‐tau or P‐tau.C, DVBM analyses for CSF T‐tau and P‐tau when adjusted for 18F‐AV‐1451.CC BY · PubMed Central
Figure 4 Associations between tau biomarkers and cognition A–CAssociations of CSF T‐tau, P‐tau, 18F‐AV1451 retention in the stage I–V composite region, hippocampal volume and cortical thickness (in the temporal lobe, “AD‐cortex”, see Materials and Methods for details) with the cognitive tests MMSE, ADAS‐cog delayed recall, and AQT colour and form naming. The estimates are β‐coefficients with 95% confidence intervals (error bars) from linear regression models adjusted for age, sex, diagnosis, education and (for hippocampal volume) intracranial volume. All data were scaled and centred. If necessary, the signs were inverted to make a more pathological biomarker associated with greater cognitive impairment. Significant associations are shown in red. In sum, higher 18F‐AV1451 retention and thinner cortex were associated with worse MMSE, ADAS‐cog delayed recall and AQT; and smaller hippocampal volume was associated with worse ADAS‐cog delayed recall and AQT.
Figure 4 Associations between tau biomarkers and cognition A–CAssociations of CSF T‐tau, P‐tau, 18F‐AV1451 retention in the stage I–V composite region, hippocampal volume and cortical thickness (in the temporal lobe, “AD‐cortex”, see Materials and Methods for details) with the cognitive tests MMSE, ADAS‐cog delayed recall, and AQT colour and form naming. The estimates are β‐coefficients with 95% confidence intervals (error bars) from linear regression models adjusted for age, sex, diagnosis, education and (for hippocampal volume) intracranial volume. All data were scaled and centred. If necessary, the signs were inverted to make a more pathological biomarker associated with greater cognitive impairment. Significant associations are shown in red. In sum, higher 18F‐AV1451 retention and thinner cortex were associated with worse MMSE, ADAS‐cog delayed recall and AQT; and smaller hippocampal volume was associated with worse ADAS‐cog delayed recall and AQT.CC BY · PubMed Central
Figure 5 Sensitivity of tau biomarkers for Alzheimer's disease A, BThe sensitivity of 18F‐AV‐1451 in different tau stage regions for preclinical AD, prodromal AD and AD dementia, and the sensitivity of 18F‐AV‐1451 in the tau stage I–V composite region, CSF T‐tau and P‐tau. Cut‐offs were defined using the mean levels plus two standard deviations in Aβ‐negative controls, as explained in the main text.
Figure 5 Sensitivity of tau biomarkers for Alzheimer's disease A, BThe sensitivity of 18F‐AV‐1451 in different tau stage regions for preclinical AD, prodromal AD and AD dementia, and the sensitivity of 18F‐AV‐1451 in the tau stage I–V composite region, CSF T‐tau and P‐tau. Cut‐offs were defined using the mean levels plus two standard deviations in Aβ‐negative controls, as explained in the main text.CC BY · PubMed Central
Figure EV3 Tau PET in preclinical AD A–FRegional 18F‐AV‐1451 by Aβ‐status in controls. The boxplots show medians and interquartile ranges. There were no significant differences between Aβ‐negative and Aβ‐positive controls (tau stage I–II region, P = 0.53; tau stage III region, P = 0.19; tau stage IV region, P = 0.63; tau stage V region, P = 0.30; tau stage VI region, P = 0.72; and tau stage I–V composite region, P = 0.31). Tests were done by linear regression models adjusted for age and sex.
Figure EV3 Tau PET in preclinical AD A–FRegional 18F‐AV‐1451 by Aβ‐status in controls. The boxplots show medians and interquartile ranges. There were no significant differences between Aβ‐negative and Aβ‐positive controls (tau stage I–II region, P = 0.53; tau stage III region, P = 0.19; tau stage IV region, P = 0.63; tau stage V region, P = 0.30; tau stage VI region, P = 0.72; and tau stage I–V composite region, P = 0.31). Tests were done by linear regression models adjusted for age and sex.CC BY · PubMed Central
Figure 6 CSF tau biomarkers in preclinical AD A, BCSF T‐tau and P‐tau were compared between Aβ‐negative and Aβ‐positive controls. Aβ‐positivity (i.e. preclinical AD) was associated with higher levels of CSF T‐tau and P‐tau, adjusted for age and sex. We also compared CSF T‐tau and P‐tau between Aβ‐negative and Aβ‐positive subjects when including all subjects with a negative 18F‐AV‐1451 signal in the tau stage I–V tau composite region (30 CN, five prodromal AD and three AD dementia patients). The Aβ‐dependent effects for CSF T‐tau and P‐tau were even greater in this group, with higher CSF T‐tau (β = 222, t = 3.9, P = 0.00048) and P‐tau (β = 22.7, t = 2.9, P = 0.0054) associated with Aβ‐positivity. The boxplots show medians and interquartile ranges.
Figure 6 CSF tau biomarkers in preclinical AD A, BCSF T‐tau and P‐tau were compared between Aβ‐negative and Aβ‐positive controls. Aβ‐positivity (i.e. preclinical AD) was associated with higher levels of CSF T‐tau and P‐tau, adjusted for age and sex. We also compared CSF T‐tau and P‐tau between Aβ‐negative and Aβ‐positive subjects when including all subjects with a negative 18F‐AV‐1451 signal in the tau stage I–V tau composite region (30 CN, five prodromal AD and three AD dementia patients). The Aβ‐dependent effects for CSF T‐tau and P‐tau were even greater in this group, with higher CSF T‐tau (β = 222, t = 3.9, P = 0.00048) and P‐tau (β = 22.7, t = 2.9, P = 0.0054) associated with Aβ‐positivity. The boxplots show medians and interquartile ranges.CC BY · PubMed Central
Figure 7 Concordance between CSF and PET tau biomarkers A–HConcordance between CSF T‐tau and 18F‐AV‐1451, and CSF P‐tau and 18F‐AV‐1451. Panels (A) and (E) include all subjects, and panels (B–D) and (F–H) include AD patients at different disease stages. The cut‐off for positive CSF T‐tau was > 542 ng/l. The cut‐off for positive CSF P‐tau was > 81 ng/l. For 18F‐AV‐1451, the cut‐offs were > 1.55, 1.35, 1.57, 1.40 and 1.30 SUVR, for tau stage I–II, III, IV, V and VI regions, respectively, and > 1.41 SUVR for the tau stage I–V composite region. Note that every participant is represented in each category on the x‐axes, since every participant was classified as positive or negative for 18F‐AV‐1451 in every tau stage region.
Figure 7 Concordance between CSF and PET tau biomarkers A–HConcordance between CSF T‐tau and 18F‐AV‐1451, and CSF P‐tau and 18F‐AV‐1451. Panels (A) and (E) include all subjects, and panels (B–D) and (F–H) include AD patients at different disease stages. The cut‐off for positive CSF T‐tau was > 542 ng/l. The cut‐off for positive CSF P‐tau was > 81 ng/l. For 18F‐AV‐1451, the cut‐offs were > 1.55, 1.35, 1.57, 1.40 and 1.30 SUVR, for tau stage I–II, III, IV, V and VI regions, respectively, and > 1.41 SUVR for the tau stage I–V composite region. Note that every participant is represented in each category on the x‐axes, since every participant was classified as positive or negative for 18F‐AV‐1451 in every tau stage region.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

See all 177

Metadata

Authors
Mattsson, N., Schöll, M., Strandberg, O., Smith, R., Palmqvist, S., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Jögi, J., Blennow, K., & Hansson, O.
Affiliations
  • Lund University (SE)
  • San Francisco VA Medical Center (US)
  • Skåne University Hospital (SE)
  • Sahlgrenska University Hospital (SE)
Corresponding author
  • Mattsson, Niklas
  • Hansson, Oskar
Venue
EMBO Molecular Medicine
Published
2017-07-25
Volume
9
Issue
9
Pages
1212-1223
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2737811824
Cited by
177
References
61
Citations by year
2026: 7 · 2025: 4 · 2024: 9 · 2023: 13 · 2022: 20 · 2021: 40 · 2020: 31 · 2019: 30 · 2018: 18 · 2017: 4
FWCI
18.65
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Vetenskapsrådet
  • H2020 European Research Council
  • Hjärnfonden
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
18F-AV-1451, tau PET, cerebrospinal fluid tau, total tau, phosphorylated tau, Alzheimer's disease, biomarkers, preclinical Alzheimer's disease, prodromal Alzheimer's disease, Alzheimer's dementia, brain atrophy, cognitive decline, disease stage
MeSH terms
Aged, Alzheimer Disease, Brain, Cognition, Female, Fluorine Radioisotopes, Humans, Male, Phosphorylation, Cohort Studies, Biomarkers, tau Proteins, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease. https://app.cochat.ai/papers/10.15252/emmm.201707809
The paper
Mattsson, N., Schöll, M., Strandberg, O., Smith, R., Palmqvist, S., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Jögi, J., Blennow, K., & Hansson, O. (2017). 18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201707809

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.